Recombinant Anti-CD3 x Anti-CXCR5 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-CXCR5 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL) therapy.
FuncS; Promising therapeutic agent
Non-Hodgkin's lymphoma (NHL)
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
CXCR5; chemokine (C-X-C motif) receptor 5; BLR1; CD185; MDR15; C-X-C chemokine receptor type 5; CXC-R5; CXCR-5; MDR-15; monocyte-derived receptor 15; Burkitt lymphoma receptor 1, GTP-binding protein; Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5)
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email